{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:28Z","timestamp":1786982188110,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T00:00:00Z","timestamp":1476230400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded by NPS Pharmaceuticals, Inc., a wholly owned indirect subsidiary of Shire."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s12020-016-1141-0","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T02:03:44Z","timestamp":1476237824000},"page":"273-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Effects of parathyroid hormone rhPTH(1\u201384) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-9546","authenticated-orcid":false,"given":"Bart L.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara J.","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores M.","family":"Shoback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hjalmar","family":"Lagast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,12]]},"reference":[{"key":"1141_CR1","first-page":"476","volume":"9","author":"T Bohrer","year":"2003","unstructured":"T. Bohrer, I. Pasteur, O. Lyutkevych, P. Fleischmann, H. Sitter, N. Donner-Banzhoff, S. Rybakov, C. Hofmann, M. Tronko, M. Rothmund, Permanent postoperative hypoparathyroidism. An epidemiological clinical study using a new questionnaire instrument. J. Ukrainian Acad. Sci. 9, 476\u2013494 (2003)","journal-title":"J. Ukrainian Acad. Sci."},{"key":"1141_CR2","unstructured":"National Organization for Rare Disorders, Hypoparathyroidism. (2014) http:\/\/www.rarediseases.org\/rare-disease-information\/rare-diseases\/byID\/703\/viewAbstract . Accessed 15 September 2016"},{"key":"1141_CR3","first-page":"3096","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"JT Potts Jr","year":"2012","unstructured":"J.T. Potts Jr., Disorders of the parathyroid gland and calcium homeostasis. In: D.L. Longo, D.L. Kasper, J.L. Jameson, A.S. Fauci, S.L. Hauser, J. Loscalzo (eds.) Harrison\u2019s Principles of Internal Medicine, 18th Edition. McGraw-Hill, New York, pp. 3096\u20133120 (2012)","edition":"18th Edn."},{"issue":"10","key":"1141_CR4","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"J.P. Bilezikian, A. Khan, J.T. Potts Jr., M.L. Brandi, B.L. Clarke, D. Shoback, H. Juppner, P. D\u2019Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26(10), 2317\u20132337 (2011)","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"1141_CR5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"D. Shoback, Hypoparathyroidism. N. Engl. J. Med. 359(4), 391\u2013403 (2008)","journal-title":"N. Engl. J. Med."},{"issue":"suppl 1","key":"1141_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4158\/EP10302.RA","volume":"17","author":"MI Khan","year":"2011","unstructured":"M.I. Khan, S.G. Waguespack, M.I. Hu, Medical management of postsurgical hypoparathyroidism. Endocr. Pract. 17(suppl 1), 18\u201325 (2011)","journal-title":"Endocr. Pract."},{"issue":"12","key":"1141_CR7","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"D.M. Mitchell, S. Regan, M.R. Cooley, K.B. Lauter, M.C. Vrla, C.B. Becker, S.A. Burnett-Bowie, M. Mannstadt, Long-term follow-up of patients with hypoparathyroidism. J. Clin. Endocrinol. Metab. 97(12), 4507\u20134514 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"20","key":"1141_CR8","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"W.G. Goodman, J. Goldin, B.D. Kuizon, C. Yoon, B. Gales, D. Sider, Y. Wang, J. Chung, A. Emerick, L. Greaser, R.M. Elashoff, I.B. Salusky, Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342(20), 1478\u20131483 (2000)","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"1141_CR9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"G.A. Block, T.E. Hulbert-Shearon, N.W. Levin, F.K. Port, Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 31(4), 607\u2013617 (1998)","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"1141_CR10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4103\/0028-3886.84342","volume":"59","author":"SK Bhadada","year":"2011","unstructured":"S.K. Bhadada, A. Bhansali, V. Upreti, S. Subbiah, N. Khandelwal, Spectrum of neurological manifestations of idiopathic hypoparathyroidism and pseudohypoparathyroidism. Neurol. India 59(4), 586\u2013589 (2011)","journal-title":"Neurol. India"},{"issue":"2","key":"1141_CR11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2265.2012.04353.x","volume":"77","author":"R Goswami","year":"2012","unstructured":"R. Goswami, R. Sharma, V. Sreenivas, N. Gupta, A. Ganapathy, S. Das, Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin. Endocrinol. (Oxf.) 77(2), 200\u2013206 (2012)","journal-title":"Clin. Endocrinol."},{"key":"1141_CR12","doi-asserted-by":"crossref","unstructured":"M.L. Brandi, J.P. Bilezikian, D. Shoback, R. Bouillon, B. Clarke, R.V. Thakker, A. Khan, J.T. Potts Jr., Management of hypoparathyroidism: Summary statement and guidelines. J. Clin. Endocrinol. Metab. 101(6):2273\u20132283 (2016)","DOI":"10.1210\/jc.2015-3907"},{"key":"1141_CR13","doi-asserted-by":"crossref","unstructured":"J.P. Bilezikian, M.L. Brandi, N.E. Cusano, M. Mannstadt, L. Rejnmark, R. Rizzoli, M.R. Rubin, K.K. Winer, U.A. Liberman, J.T. Potts Jr., Management of hypoparathyroidism: present and future. J. Clin. Endocrinol. Metab. 101(6):2313\u20132324 (2016)","DOI":"10.1210\/jc.2015-3910"},{"key":"1141_CR14","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra, W. van Biesen, O.M. Dekkers, European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173, G1\u2013G120 (2015)","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"1141_CR15","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","volume":"88","author":"AB Hodsman","year":"2003","unstructured":"A.B. Hodsman, D.A. Hanley, M.P. Ettinger, M.A. Bolognese, J. Fox, A.J. Metcalfe, R. Lindsay, Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 88(11), 5212\u20135220 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1141_CR16","doi-asserted-by":"crossref","unstructured":"M.R. Rubin, J. Sliney Jr., D.J. McMahon, S.J. Silverberg, J.P. Bilezikian, Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos. Int. 21(11), 1927\u20131934 (2010)","DOI":"10.1007\/s00198-009-1149-x"},{"issue":"10","key":"1141_CR17","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","volume":"99","author":"NE Cusano","year":"2014","unstructured":"N.E. Cusano, M.R. Rubin, D.J. McMahon, D. Irani, L. Anderson, E. Levy, J.P. Bilezikian, PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J. Clin. Endocrinol. Metab. 99(10), 3694\u20133699 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1141_CR18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","volume":"98","author":"NE Cusano","year":"2013","unstructured":"N.E. Cusano, M.R. Rubin, D.J. McMahon, C. Zhang, R. Ives, A. Tulley, J. Sliney Jr., S.C. Cremers, J.P. Bilezikian, Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J. Clin. Endocrinol. Metab. 98(1), 137\u2013144 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"1141_CR19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"M. Mannstadt, B.L. Clarke, T. Vokes, M.L. Brandi, L. Ranganath, W.D. Fraser, P. Lakatos, L. Bajnok, R. Garceau, L. Mosekilde, H. Lagast, D. Shoback, J.P. Bilezikian, Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomized, phase 3 study. Lancet Diabetes Endocrinol. 1(4), 275\u2013283 (2013)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"1141_CR20","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"T. Sikjaer, L. Rejnmark, L. Rolighed, L. Heickendorff, L. Mosekilde; Hypoparathyroid Study Group, The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J. Bone Miner. Res. 26(10), 2358\u20132370 (2011)","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"1141_CR21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clinthera.2014.04.001","volume":"36","author":"BL Clarke","year":"2014","unstructured":"B.L. Clarke, J.K. Berg, J. Fox, J.A. Cyran, H. Lagast, Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clin. Ther. 36(5), 722\u2013736 (2014)","journal-title":"Clin. Ther."},{"issue":"113","key":"1141_CR22","first-page":"S1","volume":"76","author":"Kidney Disease: Improving Global Outcomes, CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes, CKD-MBD Work Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 76(113), S1\u2013130 (2009)","journal-title":"Kidney Int. Suppl."},{"issue":"5","key":"1141_CR23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1185\/03007998109114276","volume":"7","author":"TC Stamp","year":"1981","unstructured":"T.C. Stamp, Calcitriol dosage in osteomalacia, hypoparathyroidism and attempted treatment of myositis ossificans progressiva. Curr. Med. Res. Opin. 7(5), 316\u2013336 (1981)","journal-title":"Curr. Med. Res. Opin."},{"key":"1141_CR24","unstructured":"Natpara\u00ae (parathyroid hormone) Full Prescribing Information. Shire-NPS Pharmaceuticals, Inc., Lexington, MA, (2016)."},{"issue":"12","key":"1141_CR25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1055\/s-2006-956504","volume":"38","author":"A Testa","year":"2006","unstructured":"A. Testa, V. Fant, A. De Rosa, G.F. Fiore, V. Grieco, P. Castaldi, R. Persiani, S. Rausei, D. D\u2019Ugo, G. De Rosa, Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. Horm. Metab. Res. 38(12), 821\u2013826 (2006)","journal-title":"Horm. Metab. Res."},{"issue":"9","key":"1141_CR26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.2008.644","volume":"75","author":"CM Giachelli","year":"2009","unstructured":"C.M. Giachelli, The emerging role of phosphate in vascular calcification. Kidney Int. 75(9), 890\u2013897 (2009)","journal-title":"Kidney Int."},{"issue":"18","key":"1141_CR27","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1161\/CIRCULATIONAHA.109.851873","volume":"120","author":"M Tonelli","year":"2009","unstructured":"M. Tonelli, G. Curhan, M. Pfeffer, F. Sacks, R. Thadhani, M.L. Melamed, N. Wiebe, P. Muntner, Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 120(18), 1784\u20131792 (2009)","journal-title":"Circulation"},{"issue":"10","key":"1141_CR28","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/jbmr.1964","volume":"28","author":"T Sikjaer","year":"2013","unstructured":"T. Sikjaer, A.K. Amstrup, R. Rolighed, S.G. Kjaer, L. Rejnmark, L. Mosekilde, PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects following 6 months of treatment. J. Bone Miner. Res. 28(10), 2232\u20132243 (2013)","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"1141_CR29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","volume":"21","author":"DD Bikle","year":"2014","unstructured":"D.D. Bikle, Vitamin D metabolism, mechanism of action, and clinical applications. Chem. Biol. 21(3), 319\u2013329 (2014)","journal-title":"Chem. Biol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-1141-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-016-1141-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-1141-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:53:53Z","timestamp":1498337633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-016-1141-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s12020-016-1141-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726841489.793576362","asserted-by":"object"}]},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,12]]}}}